Embecta Corp (EMBC)vsJohnson & Johnson (JNJ)
EMBC
Embecta Corp
$6.19
-0.96%
HEALTHCARE · Cap: $363.75M
JNJ
Johnson & Johnson
$266.19
-1.62%
HEALTHCARE · Cap: $657.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 9651% more annual revenue ($99.33B vs $1.02B). JNJ leads profitability with a 16.2% profit margin vs 8.6%. EMBC trades at a lower P/E of 4.4x. JNJ earns a higher WallStSmart Score of 54/100 (C-).
EMBC
Hold44
out of 100
Grade: D
JNJ
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-3.9%
Fair Value
$9.68
Current Price
$6.19
$3.49 premium
Margin of Safety
-89.3%
Fair Value
$144.28
Current Price
$266.19
$121.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Conservative balance sheet, low leverage
Strong operational efficiency at 23.7%
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Revenue declined 8.1%
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 95.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : EMBC
The strongest argument for EMBC centers on P/E Ratio, Debt/Equity, Operating Margin.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bear Case : EMBC
The primary concerns for EMBC are Altman Z-Score, Market Cap, Return on Equity.
Bear Case : JNJ
The primary concerns for JNJ are Piotroski F-Score, PEG Ratio, P/E Ratio. A P/E of 41.5x leaves little room for execution misses.
Key Dynamics to Monitor
EMBC profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
EMBC carries more volatility with a beta of 0.83 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (54/100 vs 44/100), backed by strong 16.2% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Embecta Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Embecta Corp (EMBC) is a leading medical technology company specializing in innovative insulin delivery systems aimed at enhancing diabetes management. Born from a spin-off of Becton, Dickinson and Company, Embecta provides a comprehensive portfolio of advanced products, including cutting-edge insulin pens and syringes tailored to improve patient outcomes. With a robust focus on operational excellence and customer satisfaction, Embecta is well-positioned to capitalize on growth opportunities in the rapidly expanding diabetes care market, strengthening its leadership in this vital sector.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?